COVID-19 & Pandemics

QuadroCore’s Direct Analysis Mass Spectrometer has the Potential to Revolutionize Testing for Pandemics

 


The Gap

The current approach to treat and diagnose COVID-19 clearly indicates where improvements must be made.

Below are some systematic flaws for the existing approach:

  1. Delay in testing - there have been gaps up to 14 days from the time that someone contracts the SARS-CoV-2 pathogen and is contagious, until he/she shows any symptoms. Laboratory test results take an additional 4 days.
  2. Wide range of symptoms - some people may show only mild symptoms and not be tested at all. These are the largest contributors to spreading of COVID-19.
  3. Economic downturn - as a result of the Great Lockdown, economic and social activities are cancelled to prevent spreading disease. This can easily bring our already fragile global economy to the brink of another recession.

QuadroCore's DA50 direct analysis for COVID-19 and pandemics

QuadroCore's Novel Technology

The effective way to curb the spread of COVID-19 would be to diagnose people before they show any symptoms.

QuadroCore’s AerX 200 is a portable Mass Spectrometer that can detect SARS-CoV-2 in exhaled breath of infected individuals, even those that do not show symptoms. Its cost-effective technology enables governments and organizations to perform non-invasive mass-testing that show results in seconds.

In a nutshell, QuaroCore’s AerX 200 is able to stop the spread of virus at early stages, can help governments avoid costly economic downturns without the need for shutdowns, and allow the healthcare system to rely on an affordable and robust testing technology that can test millions of people in a short period of time.

This article can be downloaded from here.

Leave a comment

Please note, comments must be approved before they are published